Product image of Noradrenaline (Norepinephrine) Aguettant (Noradrenaline Tartrate) supplied by GNH India

Noradrenaline (Norepinephrine) Aguettant

Active Ingredient:
Noradrenaline Tartrate
Origin:
EU

Noradrenaline (Norepinephrine) Aguettant (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Noradrenaline (Norepinephrine) Aguettant, is a sympathomimetic presented as an injection for intravenous use. It treats severe hypotension and various shock states in critically ill patients.

GNH India supplies Noradrenaline (Norepinephrine) Aguettant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoire Aguettant

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Noradrenaline (norepinephrine) is a vasopressor used in acute circulatory failure and related shock conditions.

  • Hypotension: restores arterial pressure in severe low‑blood‑pressure episodes.
  • Septic shock: improves perfusion pressure when sepsis causes distributive shock.
  • Cardiogenic shock: supports cardiac output and systemic vascular resistance in pump failure.
  • Cardiac arrest: provides vasoconstriction to maintain coronary perfusion during resuscitation.

How It Works

  • Norepinephrine acts as a direct agonist at alpha‑1 and beta‑1 adrenergic receptors. Stimulation of alpha‑1 receptors causes peripheral vasoconstriction, raising systemic vascular resistance and arterial pressure. Beta‑1 activation increases heart rate and myocardial contractility, enhancing cardiac output. The combined effect rapidly restores hemodynamic stability in shock states.

Side Effects

Norepinephrine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Tachycardia: increased heart rate.
  • Hypertension: elevated blood pressure.
  • Headache: pressure sensation.
  • Anxiety or restlessness.
  • Peripheral ischemia: reduced blood flow to extremities.
  • Arrhythmia: irregular heart rhythm.

Serious or Rare Side Effects

  • Myocardial ischemia: reduced heart muscle blood supply.
  • Severe hypertension: dangerously high blood pressure.
  • Tissue necrosis at infusion site.
  • Life‑threatening arrhythmic events.
  • Pulmonary edema: fluid accumulation in lungs.
  • Severe bradycardia: dangerously low heart rate.

Precautions & Warnings

Noradrenaline requires careful monitoring and specific safety measures before and during use.

  • Cardiovascular monitoring: continuous blood pressure and heart‑rate observation is essential.
  • Dosage titration: infusion rate should be adjusted according to hemodynamic response.
  • Contraindications: avoid in patients with uncorrected tachyarrhythmias.
  • Drug interactions: monitor closely when combined with MAO inhibitors or other pressor agents.
  • Pregnancy: use only if potential benefit justifies potential risk to the fetus.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Norepinephrine can interact with several drug classes, requiring vigilance to prevent adverse events.

Major Interactions (Avoid)

  • MAO inhibitors: may precipitate hypertensive crisis.
  • Tricyclic antidepressants: additive pressor effects.
  • Beta‑blockers: can blunt desired cardiac response.
  • Vasopressin: excessive vasoconstriction risk.

Moderate Interactions (Monitor Closely)

  • Inhaled anesthetics: may potentiate hypotension.
  • Calcium channel blockers: may alter vascular tone.
  • Diuretics: can affect intravascular volume and response.

Frequently Asked Questions

Noradrenaline (Norepinephrine) Aguettant is an injectable vasopressor indicated for the rapid restoration of blood pressure in severe hypotension, septic shock, cardiogenic shock, and during cardiac arrest. It is employed in intensive‑care settings where immediate hemodynamic support is required.

Norepinephrine activates alpha‑1 adrenergic receptors, causing peripheral vasoconstriction, and beta‑1 receptors, increasing heart rate and contractility. The combined effect raises systemic vascular resistance and cardiac output, quickly improving blood pressure and organ perfusion in shock states.

The specific infusion rate and total dose are determined by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. No fixed regimen is provided; dosing is individualized and titrated in real time.

Safety data for norepinephrine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Both are catecholamine vasopressors, but norepinephrine has stronger alpha‑1 activity and weaker beta‑2 effects, making it more effective for raising systemic vascular resistance without significant bronchodilation. Epinephrine provides more pronounced beta‑1 and beta‑2 stimulation, which can be advantageous in anaphylaxis but may cause greater tachycardia.

Noradrenaline (Norepinephrine) Aguettant should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging, and the solution should not be shaken vigorously before use.

The drug is supplied as a sterile injectable solution for intravenous infusion. It is typically administered through a calibrated infusion pump, allowing precise titration of the dose while continuous hemodynamic monitoring is performed.

Critical risks include severe hypertension, myocardial ischemia, arrhythmias, tissue necrosis at the infusion site, and pulmonary edema. Immediate recognition and management of these events are essential, and continuous cardiovascular monitoring is mandatory during therapy.

Patients with uncorrected tachyarrhythmias, severe peripheral vascular disease, or known hypersensitivity to norepinephrine or any excipients should not receive this medication. Use is also contraindicated in patients where excessive vasoconstriction could worsen tissue perfusion.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Noradrenaline Tartrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT